O'Sullivan D
Graduate Entry Medical School, University of Limerick, Limerick, Ireland.
Ir J Med Sci. 2017 Feb;186(1):49-55. doi: 10.1007/s11845-016-1473-z. Epub 2016 Jun 23.
Survival outcomes for childhood cancers have significantly improved. As more children are now surviving into adulthood, knowledge of the long-term effects of childhood cancer treatments has become the focus of research.
To determine what is known about the incidence of renal function impairment in childhood cancer survivors and to determine what is known about risk factors for developing renal function impairment following childhood cancer treatment.
A comprehensive literature search was preformed to identify studies that investigated renal dysfunction in patients who were diagnosed with childhood cancer and treated with potentially nephrotoxic chemotherapeutic agents. Potentially nephrotoxic chemotherapeutic agents identified in the selection criteria include ifosfamide, cisplatin, carboplatin and methotrexate.
15 papers met the inclusion criteria. Renal function impairment was reported in 15 of 15 studies included in this literature review. The incidence of ifosfamide induced nephrotoxicity varied from 1 to 50 %. This variation may be due to the heterogeneity of reported outcome measurements. Treatment with cisplatin and carboplatin was associated with hypomagnesemia. The prevalence of hypomagnesemia varied from 7 to 29 %. This variation may be due to diversity of treatment protocols. The incidence of renal dysfunction following treatment with methotrexate was reported as 1.8 % and completely reversible.
As more childhood cancer survivors are reaching adulthood, a new niche of cancer research has emerged. Researchers are now investigating the late effects due to cytotoxic treatments. Renal function impairment is a potential late effect of treatment with nephrotoxic chemotherapeutic agents including ifosfamide, cisplatin, carboplatin and methotrexate.
儿童癌症的生存结果有了显著改善。由于现在有更多儿童存活至成年,儿童癌症治疗的长期影响已成为研究重点。
确定关于儿童癌症幸存者肾功能损害发生率的已知情况,并确定关于儿童癌症治疗后发生肾功能损害的风险因素的已知情况。
进行了全面的文献检索,以识别调查被诊断为儿童癌症并接受潜在肾毒性化疗药物治疗的患者肾功能障碍的研究。入选标准中确定的潜在肾毒性化疗药物包括异环磷酰胺、顺铂、卡铂和甲氨蝶呤。
15篇论文符合纳入标准。本综述纳入的15项研究均报告了肾功能损害。异环磷酰胺诱导的肾毒性发生率在1%至50%之间。这种差异可能是由于报告的结局测量方法的异质性。顺铂和卡铂治疗与低镁血症有关。低镁血症的患病率在7%至29%之间。这种差异可能是由于治疗方案的多样性。甲氨蝶呤治疗后肾功能障碍的发生率报告为1.8%,且完全可逆。
随着越来越多的儿童癌症幸存者成年,出现了一个新的癌症研究领域。研究人员现在正在研究细胞毒性治疗的晚期影响。肾功能损害是包括异环磷酰胺、顺铂、卡铂和甲氨蝶呤在内的肾毒性化疗药物治疗的潜在晚期影响。